RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

My guess is that cor is offering the IV pro-drug formulation for RD, leaving CX 1739 for other indications. If this is so, then the RD indication could at least in principle be negotiated by itself.

Based on the other responses to your post, my sense is that it won't be possible to carve out partnerships with different entities for different indications using a common low impact. Given that cor doesn't have many low impacts to offer, and that all have similar properties, I think that, aside for the narrowly defined RD deal above, cor may have no choice but to offer low-impacts as a class, for any and all indications.

For better or worse, I'm pretty sure I'm wrong about this, but am too ignorant to know why.